牛牛AI助手已提取核心信息
Jin Medical International Ltd., a foreign private issuer, has been notified by the Nasdaq Listing Qualifications Department of non-compliance issues that could lead to the delisting of the company's securities. On December 18, 2023, the company received a letter from Nasdaq for not providing a detailed compliance plan and failing to meet the 300 Round Lot Holder requirement. Jin Medical International has requested a hearing with the Nasdaq Hearings Panel, which has stayed the delisting pending a final decision. The hearing is scheduled for March 14, 2024, where the company must show its ability to regain and maintain compliance. Further complicating matters, on February 21, 2024, Nasdaq cited the company for not filing its Form 20-F for the period ended September 30, 2023, which will also be reviewed at the hearing. Jin Medical International is currently reviewing its position and considering remedial actions to address these compliance issues.
Jin Medical International Ltd., a foreign private issuer, has been notified by the Nasdaq Listing Qualifications Department of non-compliance issues that could lead to the delisting of the company's securities. On December 18, 2023, the company received a letter from Nasdaq for not providing a detailed compliance plan and failing to meet the 300 Round Lot Holder requirement. Jin Medical International has requested a hearing with the Nasdaq Hearings Panel, which has stayed the delisting pending a final decision. The hearing is scheduled for March 14, 2024, where the company must show its ability to regain and maintain compliance. Further complicating matters, on February 21, 2024, Nasdaq cited the company for not filing its Form 20-F for the period ended September 30, 2023, which will also be reviewed at the hearing. Jin Medical International is currently reviewing its position and considering remedial actions to address these compliance issues.
纳斯达克上市资格部门已向外国私人发行人Jin Medical International Ltd. 通报了可能导致该公司证券退市的违规问题。2023年12月18日，该公司收到了纳斯达克的来信，信中原因是没有提供详细的合规计划，也没有满足300轮持有人的要求。Jin Medical International已要求与纳斯达克听证小组举行听证会，该小组在做出最终决定之前暂停了除名。听证会定于2024年3月14日举行，届时公司必须表现出其恢复和维持合规的能力。使事情更加复杂的是，纳斯达克于2024年2月21日指出，该公司没有提交截至2023年9月30日的20-F表格，该表格也将在听证会上进行审查。Jin Medical International目前正在审查其立场，并考虑采取补救措施来解决这些合规问题。
纳斯达克上市资格部门已向外国私人发行人Jin Medical International Ltd. 通报了可能导致该公司证券退市的违规问题。2023年12月18日，该公司收到了纳斯达克的来信，信中原因是没有提供详细的合规计划，也没有满足300轮持有人的要求。Jin Medical International已要求与纳斯达克听证小组举行听证会，该小组在做出最终决定之前暂停了除名。听证会定于2024年3月14日举行，届时公司必须表现出其恢复和维持合规的能力。使事情更加复杂的是，纳斯达克于2024年2月21日指出，该公司没有提交截至2023年9月30日的20-F表格，该表格也将在听证会上进行审查。Jin Medical International目前正在审查其立场，并考虑采取补救措施来解决这些合规问题。
有用
没用